tiprankstipranks

Cellectis granted orphan drug designation for CLLS52

Cellectis announced that the FDA has granted Orphan Drug Designation, or ODD, to Cellectis’ CLLS52, an Investigational Medicinal Product used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue